Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trialMin Yan, Fangzhou Xia, Yuhua Song et al.|EClinicalMedicine|2024Cited by 10
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.Min Yan, Yajing Feng, Huimin Lv et al.|Journal of Clinical Oncology|2024Cited by 7
Utidelone Plus Bevacizumab for <i>ERBB2</i>-Negative Metastatic Breast Cancer and Active Brain MetastasesMin Yan, Rongguo Qiu, Huimin Lv et al.|JAMA Oncology|2025Cited by 4